Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion

American Journal of Health-System Pharmacy

Volumn 72, Issue 5, 2015, Pages 390-395

  Berti, Andrew D ^a   Hutson, Paul R ^a   Schulz, Lucas T ^b   Webb, Aaron P ^b   Rose, Warren E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEPHALOSPORIN; GLUCOSE; SODIUM CHLORIDE; SOLVENT; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; DRUG INFUSION; DRUG STABILITY; FLUORESCENT LIGHTING; GAS EVOLUTION; HAZE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INJECTION SITE; PRECIPITATION; PRIORITY JOURNAL; ROOM TEMPERATURE; SPECTROPHOTOMETRY; TIME TO TREATMENT; Y SITE ADMINISTRATION; CHEMISTRY; DRUG INCOMPATIBILITY; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; STANDARD;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INCOMPATIBILITY; DRUG STABILITY; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; REFERENCE STANDARDS; VANCOMYCIN;

EID: 84940614314     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140369     Document Type: Article

References (27)

1. George JM, Colton BJ, Rodvold KA. National survey on continuous and extended infusions of antibiotics. Am J Health-Syst Pharm. 2012; 69:1895-904.
2. Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform beta-lactam dosing: "S" does not always mean success. J Hosp Med. 2011; 6(suppl 1):S16-23.
3. MacVane SH, Kuti JL, Nicolau DP. Prolonging beta-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014; 43:105-13.
4. McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a b-lactam for staphylococcal bacteremia. Clin Infect Dis. 2013; 57:1760-5.
5. Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51:3731-3.
6. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.
7. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49:1-45.
8. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52:427-31.
9. Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm. 1991; 48:77. Letter.
10. Szof C, Walker PC. Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. Am J Hosp Pharm. 1993; 50:2054,2057.
11. Raverdy V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother. 2013; 68:1179-82.
12. Leung E, Venkatesan N, Ly SC, Scheetz MH. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. Am J Health-Syst Pharm. 2013; 70:1163-6.
13. Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm. 1996; 53:2853-5.
14. Baririan N, Chanteux H, Viaene E et al. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother. 2003; 51:651-8.
15. IV INDEX System [online database]. Greenwood Village, CO: Thomson Healthcare (accessed 2014 Sep 12).
16. Cefepime. Trissel's 2 Clinical Pharmaceutics Database [online database]. Houston, TX: TriPharma Communications (accessed 2014 Sep 12).
17. Trissel LA, Flora KP. Stability studies: five years later. Am J Hosp Pharm. 1988; 45:1569-71.
18. Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm. 1983; 40:1159-60.
19. Nichols CA, Welsh OH. AJHP policy on manuscripts dealing with drug stability. Am J Hosp Pharm. 1988; 45:1571-2.
20. Pharmaceutical compounding-sterile preparations (general chapter 797). The United States pharmacopeia, 37th rev., and The national formulary, 32nd ed. Rockville, MD: United States Pharmacopeial Convention; 2014.
21. Cefepime package insert. Princeton, NJ: Sandoz; 2011 Oct.
22. Trissel LA, Xu QA. Stability of cefepime hydrochloride in AutoDose Infusion System bags. Ann Pharmacother. 2003; 37:804-7.
23. Calahorra B, Campanero MA, Sádaba B, Azanza JR. Rapid high-performance liquid chromatographic determination of cefepime in human plasma. Biomed Chromatogr. 1999; 13:272-5.
24. Rose WE, Knier RM, Hutson PR. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2010; 65:2149-54.
25. Xu QA, Trissel LA, Saenz CA et al. Stability of three cephalosporin antibiotics in Auto-Dose Infusion System bags. J Am Pharm Assoc. 2002; 42:428-31.
26. Dow RD, Rose WE, Fox BC et al. Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Prac. 2011; 19:413-7.
27. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589-96.